Scientific Review of the Knowledge Gap in the Efficacy of Antiviral Therapy to a Low-Risk Kidney Transplant Population Cohort
Carolynn Thomas Jones, Vincent Chidozie Iwuji*
The Ohio State University, Columbus, USA
*Corresponding author: Vincent Chidozie Iwuji, The Ohio State University, Columbus, USA.
Received Date: 28 May, 2023
Accepted Date: 06 June, 2023
Published Date: 08 June, 2023
Citation: Jones CT, Iwuji VC (2023) Scientific Review of the Knowledge Gap in the Efficacy of Antiviral Therapy to a Low-Risk Kidney Transplant Population Cohort. Int J Nurs Health Care Res 6: 1429. https://doi.org/10.29011/2688-9501.101429
Abstract
Opportunistic infection with cytomegalovirus (CMV) is a major cause of patient morbidity and mortality after renal and other solid organ transplantation [1]. De facto standard of care is choice of either prophylactic or preemptive therapy [2]. There is a knowledge gap in the efficacy of antiviral therapy to a low-risk kidney transplant population. I searched the PubMed and clinicaltrials.gov databases with strategic keywords. Although the final search yielded 52 results (PubMed) and 25 (clinicaltrials. gov), I only included 14 articles particular to the main topic of this review. There is limited data specific to this population, therefore, healthcare defaults to the de facto standard of care of choice.
Introduction
End Stage Renal Disease is an end organ diagnosis where the kidneys lose optimal functioning. Two treatment options for this disease are dialysis or kidney transplantation. Dialysis is a process of removing or filtering waste, via a machine, from the blood. Although it is effective, it is not without harmful side effects. The latest studies reveal a significant decrease in mortality with kidney transplant compared to dialysis. This is a reason why most providers encourage their patients to pursue kidney transplantation. Once a patient is transplanted, there is an expected recovery phase. Typically, the first 3 months post-operation is a high-risk period. The patient would have endured significant immunosuppression therapy, which puts the patient at risk for opportunistic infections (viral, bacterial, and/or fungal). This is the reason why antivirals, antibiotics, and antifungals are a staple regimen alongside immunotherapy.
This systematic review will focus on the antiviral regimen. Antivirals are for protection from viruses such as herpes and cytomegalovirus. Cytomegalovirus (CMV) is a major infection that can be very harmful to the donor kidney organ. CMV is a pervasive post-transplant infection, which is how it earned the nickname, the transplantation troll (Kotton, 2018). A posttransplant patient could get infected from a CMV seropositive organ or from the community. Latest research showed that 20%60% of kidney transplant recipients developed CMV within first 3 months post-transplant [3]. Various post-transplant CMV risk factors include serostatus, rejection history, host factors, and net state of immunosuppression [4]. CMV infections typically lead to febrile illness, opportunistic infections, acute graft rejection and potentially graft failure [1]. The antiviral medication of choice is high dose valacyclovir and research has explored various treatment regimen strategies, prophylaxis vs preemption or a hybrid of both (Kotton, 2018).
In the transplant community, universal prophylaxis has been accepted as the standard. Universal prophylaxis is treating all post-transplant patients, within 10 days post operation, and continuing for 3-6 months [4]. Transplant recipients that are CMV seronegative and receive donor CMV seropositive organs (D+/R) are considered high risk for CMV. The guidelines uniformly suggest six months of valganciclovir prophylaxis [4]. Transplant recipients that are CMV seropositive (R+), regardless of donor serostatus, are considered intermediate risk and recommended to receive three months of valganciclovir prophylaxis [4]. Prophylaxis disadvantages are drug toxicity, cost, antiviral resistance, delayed T cell response recovery, and late onset CMV. Preemption therapy (PET) takes a reactive approach to immunotherapy. The regimen consists of serial blood tests, symptoms monitoring, then medication treatment only if symptoms meet infection criteria [3]. However, PET doesn’t protect against herpes simplex and is logistically difficult to coordinate and monitor (Kotton, 2018). Numerous research studies concentrate on comparing the two therapy philosophies to discover the superior therapy. On the other hand, this review will focus on the efficacy of using antivirals for low-risk kidney transplant population, defined as CMV negative, hepatitis C virus (HCV) negative, and Epstein Barr virus (EBV) negative. These patients are designated as donor seronegative/ recipient seronegative (D-/R-).
Background
It is understood that post-transplant patients need protection from CMV. D+/R- patients are considered high risk for CMV as it occurs in 70% of these cases [5]. However, for patients that are not exposed to CMV, and receive an organ that isn’t exposed to CMV, there begs the question if antiviral therapy is indicated. In reviewing the latest studies, there is limited data on the efficacy of using antivirals for the low-risk kidney transplant population (D-/R-). One thing to consider is the increased risk for side effects.
Another consideration is the increased risk for CMV or other viral resistance. Antiviral, though effective options, can be limited in their effectiveness and adequateness. Acyclovir, though safe and inexpensive, is inferior to cytomegalovirus replication. Ganciclovir, another compelling option, is also susceptible to antiviral resistance [6]. Valganciclovir is costly and with significant side effects [4].
In reference to the preemption vs prophylaxis discussion, CMV DNAemia is more common with preemptive therapy, whereas late-onset CMV DNAemia or disease and neutropenia is more common with prophylaxis (Kotton, 2018).
Methods
In PubMed, I used search terms “cytomegalovirus antiviral prophylaxis transplant” (Table 1). The search yielded 2269 results. I was able to find some articles that pertained to my research questions, but I noticed the extensive dating. I adjusted the date filter to “2010-2022’ and retrieved 1043 results. As I reviewed articles, I noticed I didn’t have access to many articles of interest. I adjusted the search filter to only include “free full text” articles. The results yielded 424 articles. I chose a few articles that specifically reviewed cytomegalovirus, as an antiviral treatment for post-transplant recipients. I excluded articles that didn’t pertain to kidney or liver transplant because they share the same standard antiviral regimen. I excluded articles that reviewed antivirals other than valganciclovir because this is standard antiviral medication. The articles ranged from the American Journal of Transplantation,
Current Opinion in Infectious Diseases, the Transplantation Journal, Current Hematologic Malignancy Reports. I specifically sought articles that focused on or at least mentioned CMV seronegative donors and recipients.
("cytomegalovirus"[MeSH
Terms] OR "cytomegalovirus"[All Fields] OR
"cytomegaloviruses"[All Fields]) AND ("antiviral
agents"[Pharmacological Action] OR "antiviral agents"[MeSH Terms] OR
("antiviral"[All Fields] AND "agents"[All Fields]) OR
"antiviral agents"[All Fields] OR "antivirals"[All
Fields] OR "antiviral"[All Fields] OR "antivirally"[All Fields])
AND ("prevention and control"[MeSH Subheading] OR ("prevention"[All
Fields] AND "control"[All Fields]) OR "prevention and
control"[All Fields] OR "prophylaxis"[All Fields] OR
"prophylaxies"[All Fields] OR "prophylaxy"[All Fields])
AND ("transplantability"[All Fields] OR
"transplantable"[All Fields] OR "transplantated"[All
Fields] OR "transplantating"[All Fields] OR
"transplantation"[MeSH Terms] OR "transplantation"[All
Fields] OR "transplantations"[All Fields] OR
"transplanted"[All Fields] OR "transplanting"[All Fields]
OR "transplantation"[MeSH Subheading] OR "transplantation
s"[All Fields] OR "transplanter"[All Fields] OR
"transplanters"[All Fields] OR "transplantion"[All
Fields] OR "transplants"[MeSH Terms] OR "transplants"[All
Fields] OR "transplant"[All Fields]) |
Table 1: Initial Search Terms.
Although I came across articles that helped me frame the research introduction and background, most of the articles focused on CMV seropositive donors and seronegative recipients. Therefore, I did an additional PubMed search with terms “antiviral seronegative donor seronegative recipient transplant” (Table 2). Also, I included “free full text” and “2015- 2022” as filters. My updated search yielded 52 results. To find more information specific to the D-/R- cohort, I searched the cinicaltrials.gov database for latest data. I used key terms “CMV prophylaxis, kidney transplant” which yielded 44 results (Table 2). I applied an additional filter for completed studies, which reduced my results to 25. I excluded pediatric studies and drug intervention comparison studies. Although it was difficult to find studies specific to the D-/R- cohort, I was able to locate information on pipeline therapies to address CMV infection. The HB-101 vaccine recently completed Phase II and it included the D-/R- cohort as a control (National Library of Medicine [NLM], NCT03629080). What is interesting is that this article did not identify the D-/R- cohort as a high-risk population. Hoffmann-La Roche completed a study that looked at the effects of Ganciclovir on cohort, D+/R- and an untreated cohort D-/R- (National Library of Medicine [NLM], NCT01663740). The findings were either comparable or the D-/R- cohort showed superior findings. This isn’t surprising as they are a low-risk cohort. Figure 1 illustrates a flow chart that illustrates the search methodology.
(("antiviral
agents"[Pharmacological Action] OR "antiviral agents"[MeSH
Terms] OR ("antiviral"[All Fields] AND "agents"[All
Fields]) OR "antiviral agents"[All Fields] OR
"antivirals"[All Fields] OR "antiviral"[All Fields] OR
"antivirally"[All
Fields]) AND ("seronegative"[All Fields] OR
"seronegatives"[All Fields] OR "seronegativity"[All
Fields]) AND ("donor s"[All Fields] OR "tissue
donors"[MeSH Terms] OR ("tissue"[All Fields] AND "donors"[All
Fields]) OR "tissue donors"[All Fields] OR "donor"[All
Fields] OR "donors"[All Fields]) AND ("seronegative"[All
Fields] OR "seronegatives"[All Fields] OR
"seronegativity"[All Fields]) AND ("transplant
recipients"[MeSH Terms] OR ("transplant"[All Fields] AND
"recipients"[All Fields]) OR "transplant recipients"[All
Fields] OR ("recipient"[All Fields] AND "transplant"[All
Fields]) OR "recipient transplant"[All Fields])) AND
((ffrft[Filter]) AND (2015:2022[pdat])) |
Table 2: Second set of Search Terms.
Figure 1: Flowchart of search methodology.
The following table includes the evaluation of resources included.
Title/Author
with Full Citation |
Study
Aims and or Hypothesis |
Study
Design |
Study
Population |
Key
Findings |
Legendre,
C. M., Norman, D. J., Keating, M. R., Maclaine, G. D., & Grant, D. M. (2000).
Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal
transplantation: an economic evaluation. Transplantation, 70(10), 1463–1468.
https://doi.org/10.1097/00007890-200011270-00012 |
A
cost-effectiveness analysis of treatment with valaciclovir versus placebo was
performed, assessing the mean total cost for the number of cases of CMV
avoided at 6 months in the two groups |
multicenter
multinational randomized, placebo-controlled, double-blind trial of
valaciclovir CMV prophylaxis. Patients were stratified into donor
seropositive/recipient sero-negative (D+R-) and recipient seropositive (R+)
groups. Patients were followed up 6 months posttransplant for clinical
efficacy and 1 year for patient/allograft survival |
15
to late 70’s
Even
Male/Female ratio |
*CMV
disease incidence at 6 months posttransplant were 16% for the valaciclovir
group and 45% for placebo controls in the D+R- stratum and 1 and 6% for the
valaciclovir group and placebo controls
*The
6-month incidence of biopsy-proven acute rejection was 26% for valaciclovir
patients versus 55% for controls, and 39 vs. 63% for clinical acute rejection
*D+/R-
patients who were administered valaciclovir prophylaxis used significantly
fewer inpatient resources in several categories: number of hospital
admissions, total number of hospital days, number of special procedures, and
number of laboratory tests
* In
D+R- cohort, there were no significant differences in outpatient resource use
between the valaciclovir and placebo groups
*R+
patients had fewer ER admissions and fewer antiviral use days
*Patients
who developed CMV disease used significantly more inpatient and outpatient
resources than patients without CMV disease, regardless of treatment group
*for
both cohorts, the cost of valaciclovir was offset by saving expenditures
therefore proven economically superior strategy compared to placebo |
Couchoud,
C., Cucherat, M., Haugh, M., Pouteil-Noble, C. Cytomegalovirus Prophylaxis
with Antiviral Agents in Solid Organ Transplantation: A Meta-Analysis.
Transplantation: March 15, 1998 - Volume 65 - Issue 5 - p 641-647 |
The aim of this meta-analysis was to
assess the efficacy of antiviral agents to prevent, in solid organ transplant
recipients, CMV infection and symptomatic disease and to decrease the
incidence of acute rejection, graft loss, and death |
prospective randomized study, where one
group in the study received a prophylactic treatment with acyclovir and/or
ganciclovir (GCV) begun before the CMV infection, and a control group was not
treated or receive placebo |
adults or pediatric recipients of a
solid organ transplant |
Significant decrease in CMV infection,
however, no decrease in graft loss, acute rejection, or death |
Puius,
Y. A. & Snydman, D. R. (2007). Prophylaxis and treatment of
cytomegalovirus disease in recipients of solid organ transplants: current
approach and future challenges. Current Opinion in Infectious Diseases, 20
(4), 419-424. doi: 10.1097/QCO.0b013e32821f6026. |
Reviewing
the risks and benefits of differing strategies |
Metanalysis
of randomized controlled trials
|
D+/R-
CMV recipients |
*Hodson
et al metanalysis, prophylaxis- CMV risk reduced by 60%, mortality reduced by
40% and preemptive therapy was inconclusive
*Strippoli
et al metanalysis preemption yielded no statistical significance.
*Small
et al metanalysis preemption yielded no statistical difference in CMV
disease, graft loss, or mortality
*French
Model CEA showed oral valganciclovir prophylaxis as most cost effective when
compared to preemptive IV ganciclovir and standard therapy
*Khoury
et al showed no significant difference between prophylaxis or preemption
*Limaye
et al. retrospective analysis is most
reflective of current practice, however it does not answer question of
causality between mortality and CMV disease
*Diaz-Pedroche
trial focused on preemption with R- CMV cohort (high risk population).
*
The study results support VGCV needed by average of 58 days after transplant
*Doyle
et al provided Kaplan-Meier curve that show long term benefit for 24-week
prophylaxis
*Singh
et al trial did not show emergence of CMV resistance with preemptive VGCV
*Boivin
et al showed low incidence of CMV resistance with prophylactic GCV and VGCV |
Boillat
Blanco, N., Pascual, M., Venetz, J., Nseir, G., Meylan, P., Manuel, O. Impact
of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus
Prophylaxis in Kidney Transplant Recipients. Transplantation: January 27,
2011. Volume 91(2),p 251-255 doi: 10.1097/TP.0b013e318200b9f0 |
Assess impact of preemptive strategy,
after discontinuing antiviral prophylaxis, in prevention of late onset CMV;
primary endpoint was incidence of late-onset CMV |
Prospective, non-controlled, single
center
All patients receive 3 mos prophylaxis
VGCV, then monitor for CMV by PCR Q15days for 3 mos. VGCV restarted if PCR
positive |
86 kidney transplant recipients,
average age 48 years, 60Male 26Female 30 D+/R- 56 R+
|
*CMV occurred in 36% recipients; 43% in D+/R- 32% in R+
*None from the R+ group developed late
onset CMV, and their PCR results were below threshold
*Preemption strategy seems to have a
limited impact on the prevention of late-onset CMV disease, particularly in
group of seropositive CMV patients |
van
der Beek, M., Berger, S., Vossen, A., van der Blij-de Brouwer, C., Press, R.,
de Fijter, J., Claas, E., Kroes, A., loys, C. Preemptive Versus Sequential
Prophylactic-Preemptive Treatment Regimens for Cytomegalovirus in Renal
Transplantation: Comparison of Treatment Failure and Antiviral Resistance.
Transplantation: February 15, 2010 - Volume 89 - Issue 3 - p 320-326 doi:
10.1097/TP.0b013e3181bc0301 |
Compare
the incidence and course of CMV infections, frequency of treatment failure of
CMV infections, and role of antiviral resistance |
*Retrospective Single
center
*42
treated preemptive and 29 treated prophylactic
*Prior
to 2006, preemptive regimen started, guided by CMV DNA load.
*Treatment
started once CMV load threshold reached. From 2006, prophylaxis regimen
started x90 days, followed by preemption. |
*78
D+/R- kidney-pancreas transplant recipients
*Mean
age Prophylaxisn49;
preemptionn46
*Males Prophylaxis
n24; Preemption n18
|
*Incidence
of CMV was similar for both cohorts
*Preemption
cohort had significantly higher CMV 69% vs 45%
*No
CMV end organ disease occurred in any cohort
*No
significant difference in # of rejection episodes or renal function between
the cohorts
*Treatment
failure, defined by DNA load, was higher in preemption group 71% vs 14% &
duration of preemption treatment was longer with preemption cohort 45 days vs
29 days
*Sequential
prophylaxis-preemptive approach proved practical
*CMV
infections with a slow response to preemptive antiviral treatment occurred
less frequently in patients who had received prophylactic treatment than in
patients on a strictly preemptive regimen.
*CMV
infections with resistant virus were eventually cleared without switching
antiviral therapy
|
Khoury,
J. A. , Storch, G. A. , Bohl, D. L. , Schuessler, R. M. , Torrence, S. M. ,
Lockwood, M. , Gaudreault-Keener, M. , Koch, M. J. , Miller, B. W. ,
Hardinger, K. L. , Schnitzler, M. A. & Brennan, D. C. (2006).
Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus
Infection in Adult Renal Transplant Recipients. American Journal of
Transplantation, 6 (9), 2134-2143. |
*Our study compares outcomes and costs
of adult renal transplant recipients randomized to receive prophylactic or
preemptive oral valganciclovir for the clinical management of CMV infection
*The primary outcome for the purpose of
powering the study was an economic comparison between the prophylactic and
preemptive groups. Secondary outcomes included occurrence of CMV infection
and disease, clearance of CMV DNAemia, incidence of acute rejection,
allograft survival, allograft dysfunction, death, and incidence of
neutropenia. |
*Randomized single center
*Prophylaxis cohort (n50), preemption
cohort (n49) with VGCV ,1:1 block design stratified by CMV serostatus
*Monitored by PCR before transplant
then weekly for 16 wks post-transplant, then at months 5, 6, 9, 12
*Prophylaxis group received VGCV for
100 days post-transplant while preemption only received if PCR detected
*Prophylaxis group (age 52 years, male
51%, white 80%) Preemption group (age 49, male 23%, white 90%)
|
*CMV risk population D+/R+, D+/R-, D-/R+
*D-/R- (n20) were included, but only to
monitor (control)
*144 adult patients |
*No deaths occurred
*99% overall allograft survival rate
*Rejection (proph n1, preemp n4)
*No relationship observed between CMV
and acute rejection
*No difference in serum creatinine
between cohorts
*Prophylaxis reduced occurrence of CMV
by 90% during first 100 days and by 52% for entire study compared to
preemption
*In preemption cohort, CMV onset
occurred only in first 100 days (avg by 39 days post txp)
*Recurrent CMV higher in preemptive
cohort (n34 vs n14)
*This randomized study found that
prophylaxis or preemptive treatment with valganciclovir were each associated
with low rates of symptomatic CMV (5%) in kidney transplant recipients
*No evidence of CMV recurrence
*Symptoms in CMV-proph group (n4) after
100 days treatment; preemption (n1) by 61 days post-transplant
*D-/R- cohort only had n2 (10%) with
CMV DNAemia
*Costs were favorable to preemption
(VGCV, hospitalization) but favorable to proph (provider time, CMV PCR
testing)
*Preemption results suggests
correlation with low risk of CMV recurrence in D+/R- group
*3 suggested therapies based on
results: (1) preemptive, since in this study the overall incidence of CMV
DNAemia was similar, but symptomatic CMV was less than with prophylaxis; (2)
extended prophylaxis to 6–12 months (26, 27) or (3) prophylaxis to
approximate 100 days followed by monitoring and preemptive therapy.
*Prophylaxis more effective in reducing
CMV occurrence, however less effective in preventing symptomatic disease in
D+/R- patients |
Hibberd,
P. L., Tolkoff-Rubin, N. E., Cosimi, A. B., Schooley, R. T., Isaacson, D.,
Doran, M., Delvecchio, A., Delmonico, F. L., Auchincloss, H., Jr, &
Rubin, R. H. (1992). Symptomatic cytomegalovirus disease in the
cytomegalovirus antibody seropositive renal transplant recipient treated with
OKT3. Transplantation, 53(1), 68–72.
https://doi.org/10.1097/00007890-199201000-00013 |
Define
particularly high-risk groups |
*Prospective,
single center
*Cohorts
with differing immunosuppressive regimens |
*n94
renal transplant recipients
*Age
>18 years
|
*D-/R-
(N37) were at no risk for CMV
*Antivirals
are necessary to prevent CMV in CMV seropositive recipients
*Antiviral
strategies are necessary in CMV seropositive patient; however a preemptive
strategy would be more cost effective and logistically feasible approach |
Hakki
M. (2020). Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Current hematologic malignancy reports, 15(2), 90–102.
https://doi.org/10.1007/s11899-020-00557-6 |
This review will discuss recent
developments in CMV antiviral agents and non-pharmacologic interventions that
may augment the ability to prevent and treat CMV infections in recipients |
|
|
*Adoptive therapy entails
reconstitution of CMV specific T cells by transfusion of donor T cells
*IVIG not effective in CMV therapy -*Monoclonal
antibody therapy still in development |
Stamps,
H., Linder, K., O'Sullivan, D. M., Serrano, O. K., Rochon, C., Ebcioglu, Z.,
Singh, J., Ye, X., Tremaglio, J., Sheiner, P., Cheema, F., & Kutzler, H.
L. (2021). Evaluation of cytomegalovirus prophylaxis in low and intermediate
risk kidney transplant recipients receiving lymphocyte-depleting induction.
Transplant infectious disease: an official journal of the Transplantation
Society, 23(4), e13573. https://doi.org/10.1111/tid.13573 |
*Evaluate
if this recently implemented
change in CMV prophylaxis strategy based on serostatus has resulted in a
change in incidence of post-transplant CMV
*Viremia
in D-/R- and R+ cohort who received lymphocyte-depleting induction
therapy.
*Primary
outcome was incidence of CMV viremia within first year post transplant.
*Secondary
outcome includes CMV syndrome incidence (fevers, myalgias, fatigue etc.),
biopsy proven CMV, leukopenia or neutropenia, CMV related hospitalization,
and biopsy-proven rejection |
*Retrospective
*pre-post
intervention
*Single
site Cohort: R+
(historic)- received 120 days prophylaxis
R+
(experiment)- received less than 120 days prophylaxis
D-/R-
(historic) received valganciclovir
D-/R-
(experimental) received valacyclovir
|
*Adult
kidney recipient
*Age
>18 years
*205
patients |
*No
viremia for D/R- cohort
*No
significant difference in CMV viremia in R+ groups
*No
significant difference of CMV syndrome between the groups
*No
significant difference in cohorts which validates 3 mos CMV prophylaxis as an
effective strategy
*Results
that there is no increased risk of
rejection or disease despite a shorter duration of VGCV
use
*No
correlation that aggressive VGCV prophylaxis strategy reduces the incidence
of CMV viremia in
D-/R- or R+ cohort who received lymphocyte-depleting induction |
Kotton,
C. N., Kumar, D., Caliendo, A. M., Huprikar, S., Chou, S., Danziger-Isakov,
L., Humar, A., & The Transplantation Society International CMV Consensus
Group (2018). The Third International Consensus Guidelines on the Management
of Cytomegalovirus in Solid-organ Transplantation. Transplantation, 102(6),
900–931. https://doi.org/10.1097/TP.0000000000002191 |
|
|
|
*Regarding D-/R-, there is minimal risk
of CMV infection, and routine prevention of CMV is not necessary *Antiviral prophylaxis against other
herpes infections (especially disseminated varicella and herpes simplex) with
acyclovir, famciclovir, or valacyclovir should be considered |
David-Neto,
Elias (2011, November - 2013, July). Definition of Cut Off for PCR -
Quantitative and Antigenemia in the Diagnosis of Cytomegalovirus (CMV)
Disease in Serum-positive Kidney Transplant Recipients. Identifier
NCT01573039. https://clinicaltrials.gov/ct2/show/NCT01573039?term=CMV+prophylaxis&recrs=e&cond=kidney+transplant&draw=2&rank=2 |
*Establish
a cutoff for viremia, antigenemia detected by PCR and quantitative-to event
for CMV disease |
*Observational
prospective
*Randomized
parallel |
*120
participants
*Age
14-75 years
*non-probability
kidney transplant recipient sample
*CMV
seropositive |
*Seronegative
patients receive 90-day GCV prophylaxis
*Seropositive
patients undergo surveillance for early viremia detection
|
Schwendinger,
M., Thiry, G., De Vos, B., Leroux-Roels, G., Bruhwyler, J, Huygens, A.,
Ganeff, C., Buchinger, H., Orlinger, K.,
Pinschewer, D., Monath, T., Lilja, A. A Randomized Dose-Escalating
Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus
Vector-Based Vaccine Against Human Cytomegalovirus, The Journal of Infectious
Diseases, Volume 225, Issue 8, 15 April 2022, Pages 1399–1410,
https://doi.org/10.1093/infdis/jiaa121 |
*First in-human Phase I trial to assess
the safety and immunogenicity of 3 administrations of the candidate vaccine
at ascending doses in healthy seronegative adult volunteers. |
*Randomized, double-blind, sequential
*Dose-escalation Phase I study
*Parallel cohorts |
*CMV seronegative
*Age 18-45yrs |
*Vaccine associated with mild-moderate
adverse events
*Vaccine was otherwise well tolerated
and produced the preferred outcomes |
Hookipa
Biotech GmbH. (2018, December 12 - 2022, June 22). A Study of CMV Vaccine
(HB-101) in Kidney Transplant Patients. Identifier NCT03629080. https://clinicaltrials.gov/ct2/show/study/NCT03629080?term=CMV+prophylaxis&recrs=e&cond=kidney+transplant&draw=2&rank=16 |
to
assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in
adult patients |
*Phase
II *Randomized double-blind Interventional parallel |
*83
participants
*CMV
seronegative |
|
Hoffmann-La
Roche. (2012, January 30 - 2016, December 30). A Study on Spermatogenesis in
Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus
Untreated Matched Controls. Identifier NCT01663740.
https://clinicaltrials.gov/ct2/show/study/NCT01663740?term=CMV+prophylaxis&recrs=e&cond=kidney+transplant&draw=2&rank=19 |
*To compare spermatogenesis in male
adult renal transplant recipients receiving valganciclovir versus untreated
matched controls |
*Randomized multicenter prospective
interventional study |
*59 participants
*Males, age 20-50 years |
|
Table 3: Table of Included Studies.
Title/Author
with Full Citation |
Strengths
and Limitation of Study |
Other
Comments |
Legendre,
C. M., Norman, D. J., Keating, M. R., Maclaine, G. D., & Grant, D. M.
(2000). Valaciclovir prophylaxis of cytomegalovirus infection and disease in
renal transplantation: an economic evaluation. Transplantation, 70(10),
1463–1468. https://doi.org/10.1097/00007890-200011270-00012 |
*Medical
Resource Use (MRU) and costs not standardized across hospital systems *Applicable
to French health care context Only
analyzed 6month post-transplant period |
*Study
population did not include D-/R- cohort |
Couchoud,
C., Cucherat, M., Haugh, M., Pouteil-Noble, C. Cytomegalovirus Prophylaxis
with Antiviral Agents in Solid Organ Transplantation: A Meta-Analysis.
Transplantation: March 15, 1998 - Volume 65 - Issue 5 - p 641-647 |
Because
not all the authors performed routine viral monitoring, the exact incidence
of cytomegalovirus infection could not be assessed for all trials. |
To
date, there is no evidence to suggest that cytomegalovirus prophylaxis should
be prescribed to reduce the incidence of acute or chronic rejection |
Puius,
Y. A. & Snydman, D. R. (2007). Prophylaxis and treatment of
cytomegalovirus disease in recipients of solid organ transplants: current
approach and future challenges. Current Opinion in Infectious Diseases, 20
(4), 419-424. doi: 10.1097/QCO.0b013e32821f6026. |
*Randomized
control study
*No
clear effect on acute rejection
*Sparse
data for preemptive therapy
*No
data on seronegative donor and seronegative recipient |
*Strippoli
et al. meta analysis, 17.8% patients (64/358) excluded because of early CMV
onset (days 0-10)
*Endpoints
of rejection and mortality not addressed
*Prophylaxis
relies on costly drugs
*Preemption
relies on costly testing for CMV monitoring
*And
the treatments for CMV & rejection are costly
*Resistance
can occur in the absence of prophylaxis |
Boillat
Blanco, N., Pascual, M., Venetz, J., Nseir, G., Meylan, P., Manuel, O. Impact
of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus
Prophylaxis in Kidney Transplant Recipients. Transplantation: January 27,
2011. Volume 91(2),p 251-255 doi: 10.1097/TP.0b013e318200b9f0 |
*Data from first period of study
collected retrospectively
*No control group
*Small cohort sample
*Strengths were a homogeneous
population, prophylactic protocols & follow-up, PCR testing quality, and
viral load monitoring schedule |
D-/R- patients were excluded |
van
der Beek, M., Berger, S., Vossen, A., van der Blij-de Brouwer, C., Press, R.,
de Fijter, J., Claas, E., Kroes, A., loys, C. Preemptive Versus Sequential
Prophylactic-Preemptive Treatment Regimens for Cytomegalovirus in Renal
Transplantation: Comparison of Treatment Failure and Antiviral Resistance.
Transplantation: February 15, 2010 - Volume 89 - Issue 3 - p 320-326 doi:
10.1097/TP.0b013e3181bc0301 |
|
The
cost effectiveness of both regimens is a relevant aspect in decision making.
Costs may vary locally but depend among other things on the number of samples
for CMV DNA load measurement, the amount of antiviral medication
administered, and the number of admissions for CMV infections |
Khoury,
J. A. , Storch, G. A. , Bohl, D. L. , Schuessler, R. M. , Torrence, S. M. ,
Lockwood, M. , Gaudreault-Keener, M. , Koch, M. J. , Miller, B. W. ,
Hardinger, K. L. , Schnitzler, M. A. & Brennan, D. C. (2006). Prophylactic
Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus
Infection in Adult Renal Transplant Recipients. American Journal of
Transplantation, 6 (9), 2134-2143. |
|
*Both options were effective, minimal
side effects, and low rates of adverse outcomes
*D-/R- & preemption cohorts
received acyclovir x100 days post-transplant for herpes prophylaxis
*No significant side effects of oral
VGCV
*No clinical or viral evidence of
resistance
*Costs evaluation suggests the transplant
center may need to absorb the PCR testing and that MCR part D significantly
covers VGCV |
Hibberd,
P. L., Tolkoff-Rubin, N. E., Cosimi, A. B., Schooley, R. T., Isaacson, D.,
Doran, M., Delvecchio, A., Delmonico, F. L., Auchincloss, H., Jr, & Rubin,
R. H. (1992). Symptomatic cytomegalovirus disease in the cytomegalovirus
antibody seropositive renal transplant recipient treated with OKT3.
Transplantation, 53(1), 68–72.
https://doi.org/10.1097/00007890-199201000-00013 |
|
*More
than 50% of patients transplanted are CMV seropositive
*CMV
defined as unexplained fever (greater than 38.0 for 3+consecutive days and
positive blood or urine sample
*Allograft
rejection defined as elevation in serum creatinine of at least 0.4mg/dl,
usually with reduced urine output and renal biopsy |
Hakki
M. (2020). Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Current hematologic malignancy reports, 15(2), 90–102.
https://doi.org/10.1007/s11899-020-00557-6 |
|
*Table 1- anti CMV agents with listed toxicities
*Several CMV vaccines are still in
Phases I and II pipeline
*More randomized studies needed to
assess safety & benefit of adoptive immunotherapy and passive
immunization as they may be more realistic, viable option
*Need to determine if combo therapy is
superior to monotherapy |
Stamps,
H., Linder, K., O'Sullivan, D. M., Serrano, O. K., Rochon, C., Ebcioglu, Z.,
Singh, J., Ye, X., Tremaglio, J., Sheiner, P., Cheema, F., & Kutzler, H.
L. (2021). Evaluation of cytomegalovirus prophylaxis in low and intermediate
risk kidney transplant recipients receiving lymphocyte-depleting induction.
Transplant infectious disease: an official journal of the Transplantation
Society, 23(4), e13573. https://doi.org/10.1111/tid.13573 |
*Compared
to other antivirals, valganciclovir increases neutropenia risk by 263%
*Did
not evaluate WBC/ANC
*R+
cohort had 105 fewer days of exposure which equates to healthcare cost
savings
*Confounding
factors include retrospective design, small sample size, missing data |
*Average
US cost of 3 mos VGCV prophylaxis costs $3853 |
David-Neto,
Elias (2011, November - 2013, July). Definition of Cut Off for PCR -
Quantitative and Antigenemia in the Diagnosis of Cytomegalovirus (CMV)
Disease in Serum-positive Kidney Transplant Recipients. Identifier
NCT01573039.
https://clinicaltrials.gov/ct2/show/NCT01573039?term=CMV+prophylaxis&recrs=e&cond=kidney+transplant&draw=2&rank=2 |
|
* Preemptive treatment is suggested |
Table 4: Study Evaluation Table.
Results
The results of the integrative review indicate, for cytomegalovirus prophylaxis, there is no common opinion concerning its necessity and efficacy [6]. A search specific to the D-/R- cohort was lacking. Instead, there were far more articles investigating treatment strategies, prophylaxis vs preemption. Though, no strategy proved significantly dominant over the other. Preemption is less costly than prophylaxis, but it requires frequent monitoring and still carries risks of rejection, dysfunction, and infections [7]. Meta-analyses & pooled analyses found no difference in mortality, graft loss, and acute rejection, between prophylaxis vs preemption and none were identified as an independent risk factor of graft loss (Kotton, 2018).
Discussion
The trend in research is primarily focused on high-risk patients, and low risk patients have been insistently lumped into the consensus. It would be beneficial to the patient to avoid unnecessary medications, to minimize the identified risks. That is not to say that other infection risks should not be considered. Antiviral prophylaxis against other herpes infections (especially disseminated varicella and herpes simplex) with acyclovir, famciclovir, or valacyclovir should be considered (Kotton, 2018). It goes without saying that there should be ongoing efforts to investigate the correlation between cell-mediated immunity against CMV and high risk CMV infection [3]. One study estimated that monitoring CMV plasma viral load would have avoided approx. 1/3 of late onset CMV cases, however there are no subsequent studies that evaluate this in routine clinical practice [8-10,3]. At this point, we can deduce that CMV prevention is not warranted for a low risk CMV seronegative donor/recipient cohort.
Conclusion
All in all, this review makes the case for further exploration into how to achieve this goal. A study can conduct a cost utility analysis to compare QALYs between the generally medicated vs the preemption prophylactic approach. A cost of illness analysis can compare indirect/direct costs. Another option is a cost benefit analysis to investigate the difference in net benefits between both approaches.
Acknowledgement
I thank Dr. Parul Patel (Sutter Health Department of Transplantation) for his expertise and assistance throughout all aspects of writing this manuscript.
References
- Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM (2000) Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 70: 1463-1468.
- Puius YA, Snydman DR (2007) Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges. Curr Opin Infect Dis 20: 419424.
- Blanco NB, Pascual M, Venetz JP, Nseir G, Meylan PR (2011) Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients. Transplantation 91: 251-255.
- Stamps H, Linder K, O’Sullivan DM, Serrano OK, Rochon C, et al. (2021) Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocytedepleting induction. Transplant infectious disease : an official journal of the Transplantation Society 23: e13573.
- van der Beek, Martha T, Berger, Stefan P, Vossen, et al. (2010) Preemptive Versus Sequential Prophylactic-Preemptive Treatment Regimens for Cytomegalovirus in Renal Transplantation: Comparison of Treatment Failure and Antiviral Resistance. Transplantation 89: 320-326.
- Couchoud C, Cucherat M, Haugh M, Noble PC (1998) Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a metaanalysis. Transplantation 1998: 641-647.
- Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, et al. (2006). Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients. Am J Transplant 6: 2134-2143.
- Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, et al. (1992) Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53: 68-72.
- Hakki M (2020) Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. Current hematologic malignancy reports 15: 90-102.
- David-Neto, Elias (2013) Definition of Cut Off for PCR - Quantitative and Antigenemia in the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients. Identifier NCT01573039.